ETON
Eton Pharmaceuticals, Inc. NASDAQ Listed Nov 13, 2018$31.08
Pre-mkt
$29.85
+0.47%
Mkt Cap $848.0M
52w Low $13.09
93.6% of range
52w High $32.31
50d MA $22.74
200d MA $18.46
P/E (TTM)
-170.0x
EV/EBITDA
111.8x
P/B
29.7x
Debt/Equity
1.2x
ROE
-17.6%
P/FCF
44.6x
RSI (14)
—
ATR (14)
—
Beta
0.97
50d MA
$22.74
200d MA
$18.46
Avg Volume
368.6K
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
21925 West Field Parkway · Deer Park, IL 60010-7208 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | 0.12 | 0.05 | -58.3% | 20.77 | +3.0% | +7.5% | +6.7% | -3.5% | +3.8% | -1.6% | — |
| Nov 6, 2025 | AMC | 0.16 | -0.07 | -143.8% | 19.14 | +0.0% | -11.7% | +0.1% | +4.4% | -1.1% | -3.3% | — |
| Aug 7, 2025 | AMC | -0.01 | -0.10 | -900.0% | 15.26 | +11.5% | +12.3% | -0.5% | +1.6% | -1.2% | -2.5% | — |
| May 13, 2025 | AMC | 0.09 | 0.07 | -22.2% | 17.07 | +11.3% | +0.3% | +15.1% | -3.9% | +3.4% | +0.2% | — |
| Mar 18, 2025 | AMC | -0.02 | -0.02 | +0.0% | 14.68 | +2.2% | +1.4% | -0.7% | -3.8% | +4.0% | -7.1% | — |
| Nov 12, 2024 | AMC | 0.00 | 0.02 | +400.0% | 9.17 | +9.1% | +15.6% | -1.3% | -4.2% | +0.1% | +4.7% | — |
| Aug 8, 2024 | AMC | -0.07 | -0.12 | -71.4% | 3.62 | +0.8% | +2.8% | +0.8% | +0.5% | +7.7% | -1.2% | — |
| May 9, 2024 | AMC | -0.07 | -0.03 | +57.1% | 3.44 | +7.6% | -0.3% | +3.5% | +2.3% | +0.6% | +0.0% | — |
| Mar 14, 2024 | AMC | -0.04 | -0.09 | -125.0% | 4.46 | -10.3% | -13.7% | -9.6% | +1.7% | -1.1% | +3.4% | — |
| Nov 9, 2023 | AMC | -0.10 | -0.02 | +80.0% | 4.53 | -0.9% | -15.2% | -6.8% | +3.6% | -0.5% | -4.3% | — |
| Aug 10, 2023 | AMC | -0.09 | 0.15 | +266.7% | 2.60 | +28.5% | +38.1% | +12.5% | +17.3% | -8.4% | -8.1% | — |
| May 11, 2023 | AMC | -0.14 | -0.10 | +28.6% | 3.47 | -3.5% | +4.0% | -1.9% | +1.7% | +2.5% | -1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.77 | $21.40 | +3.0% | +7.5% | +6.7% | -3.5% | +3.8% | -1.6% |
| Mar 20 | B. Riley Securities | Maintains | Buy → Buy | — | $20.77 | $21.40 | +3.0% | +7.5% | +6.7% | -3.5% | +3.8% | -1.6% |
| Mar 20 | Craig-Hallum | Maintains | Buy → Buy | — | $20.77 | $21.40 | +3.0% | +7.5% | +6.7% | -3.5% | +3.8% | -1.6% |
| Mar 3 | Craig-Hallum | Maintains | Buy → Buy | — | $18.15 | $17.73 | -2.3% | -3.9% | +0.5% | -1.7% | -2.6% | -0.6% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.99 | $17.05 | +0.4% | +6.8% | -3.9% | +0.5% | -1.7% | -2.6% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.08 | $21.00 | +4.6% | -5.8% | -0.2% | -0.3% | -8.3% | -1.9% |
| May 16 | B. Riley Securities | Maintains | Buy → Buy | — | $19.70 | $19.62 | -0.4% | -3.9% | +3.4% | +0.2% | +3.3% | +0.0% |
| May 14 | Craig-Hallum | Maintains | Buy → Buy | — | $17.07 | $19.00 | +11.3% | +0.3% | +15.1% | -3.9% | +3.4% | +0.2% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.68 | $15.01 | +2.2% | +1.4% | -0.7% | -3.8% | +4.0% | -7.1% |
| Mar 19 | Craig-Hallum | Maintains | Buy → Buy | — | $14.68 | $15.01 | +2.2% | +1.4% | -0.7% | -3.8% | +4.0% | -7.1% |
| Mar 19 | B. Riley Securities | Maintains | Buy → Buy | — | $14.68 | $15.01 | +2.2% | +1.4% | -0.7% | -3.8% | +4.0% | -7.1% |
| Jan 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.66 | $14.90 | +1.6% | +10.8% | +2.6% | -1.3% | +7.2% | -3.2% |
| Jan 8 | Craig-Hallum | Maintains | Buy → Buy | — | $11.99 | $11.78 | -1.8% | +0.2% | +11.9% | +4.2% | -4.1% | +6.6% |
| Jan 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.00 | $13.66 | +5.1% | -6.5% | -1.4% | +0.2% | +11.9% | +4.2% |
| Nov 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.03 | $12.20 | +1.4% | +3.5% | +2.3% | +6.2% | -7.9% | -5.1% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.17 | $10.00 | +9.1% | +15.6% | -1.3% | -4.2% | +0.1% | +4.7% |
| Oct 28 | Craig-Hallum | Maintains | Buy → Buy | — | $8.11 | $8.20 | +1.1% | +3.8% | +1.4% | +1.9% | -2.6% | +1.8% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.91 | $7.00 | +1.3% | +1.3% | +4.3% | +1.4% | +4.3% | +1.4% |
| Oct 4 | Craig-Hallum | Maintains | Buy → Buy | — | $6.91 | $7.00 | +1.3% | +1.3% | +4.3% | +1.4% | +4.3% | +1.4% |
| Dec 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.60 | $3.61 | +0.3% | +9.2% | +1.0% | +8.8% | +0.0% | +3.0% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.60 | $3.34 | +28.5% | +38.1% | +12.5% | +17.3% | -8.4% | -8.1% |
| Jul 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.49 | $3.54 | +1.4% | +0.6% | -1.1% | -5.8% | -0.6% | +0.0% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.94 | $4.01 | +1.8% | +3.3% | -2.2% | +1.5% | -0.5% | +1.4% |
| Sep 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.07 | $2.16 | +4.3% | -1.4% | +3.9% | +1.9% | -1.9% | -0.9% |
| Jul 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.72 | $2.71 | -0.4% | -0.7% | -1.5% | +1.1% | +1.9% | -2.2% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.27 | $4.23 | -0.9% | +1.4% | -0.5% | +3.2% | -4.0% | -2.8% |
| Mar 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.92 | $7.70 | -2.8% | +1.3% | +2.5% | -2.8% | -4.3% | -6.4% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.13 | $8.18 | +0.6% | -0.2% | +0.1% | -2.3% | +1.8% | +3.7% |
| Sep 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.82 | $8.38 | +7.2% | +1.0% | -8.5% | -3.7% | +0.1% | -4.6% |
| May 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.78 | $4.85 | +1.5% | +1.0% | +0.4% | -5.8% | +0.7% | +8.9% |
| May 15 | B. Riley Securities | Maintains | Buy → Buy | — | $5.20 | $4.70 | -9.6% | -8.7% | -1.1% | -0.2% | +1.1% | +0.0% |
| May 15 | B. Riley FBR | Maintains | Buy → Buy | — | $5.20 | $4.70 | -9.6% | -8.7% | -1.1% | -0.2% | +1.1% | +0.0% |
| Mar 30 | H.C. Wainwright | Maintains | Buy → Buy | — | $4.36 | $4.59 | +5.3% | -8.3% | +2.5% | -2.7% | -7.3% | -5.4% |
| Jan 28 | H.C. Wainwright | Maintains | Buy → Buy | — | $6.39 | $6.87 | +7.5% | +8.0% | +1.2% | -1.6% | -3.1% | +0.5% |
| Oct 23 | H.C. Wainwright | Maintains | Buy → Buy | — | $6.43 | $6.39 | -0.6% | -3.4% | -5.6% | +0.7% | -0.8% | +2.2% |
| Sep 20 | B. Riley | Maintains | Buy → Buy | — | $6.67 | $6.90 | +3.4% | +7.0% | -4.5% | -1.0% | -7.0% | +0.8% |
| Jun 10 | H.C. Wainwright | Maintains | Buy → Buy | — | $8.14 | $7.99 | -1.8% | -2.1% | -1.0% | +0.4% | +1.0% | -3.1% |
No insider trades available.
8-K · 8.01
!! High
Eton Pharmaceutcials, Inc. -- 8-K 8.01: Material Event / Announcement
Eton Pharmaceuticals filed an 8-K disclosing a material event on April 27, 2026, though specific details require reviewing the attached press release exhibit.
Apr 27
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Eaton's CEO transition effective June 1, 2026, signals planned leadership continuity that should provide stability for the industrial conglomerate's strategic direction and investor confidence.
Apr 16
— 8-K filing (ETON, FISI)
Apr 15
8-K · 1.01
! Medium
Unknown — 8-K 1.01: Financing / Debt Agreement
Teton Energy obtained $11.8M in debt financing, increasing financial flexibility for operations but adding leverage that could pressure future cash flows and dilute shareholder equity if not deployed profitably.
Apr 15
8-K
Unknown — 8-K Filing
ETON is using Adjusted EBITDA to present a rosier financial picture than GAAP results, signaling potential underlying profitability concerns that investors should scrutinize carefully.
Mar 19
8-K · 2.01
!!! Very High
Eton Pharmaceutcials, Inc. -- 8-K 2.01: Acquisition Completed
Eton Pharmaceuticals completed an acquisition of assets, though the filing summary lacks specifics on the target company, purchase price, or strategic rationale for the transaction.
Mar 2
8-K · 8.01
!! High
Eton Pharmaceutcials, Inc. -- 8-K 8.01: Material Event / Announcement
Eton Pharmaceuticals received FDA approval for DESMODA (desmopressin acetate) oral solution to treat central diabetes insipidus, potentially establishing a new revenue stream in this specialized endocrine disorder market.
Feb 25
8-K · 8.01
!! High
Eton Pharmaceutcials, Inc. -- 8-K 8.01: Material Event / Announcement
Eton Pharmaceuticals transferred marketing rights for an ultra-rare disease product to another party on February 2, 2026, potentially reducing revenue streams but allowing focus on core pipeline assets.
Feb 2
Data updated apr 25, 2026 7:50am
· Source: massive.com